# OnCo record scorpion-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/scorpion-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "scorpion-therapeutics" ;
  schema:name "Scorpion Therapeutics"@en ;
  schema:description "Scorpion Therapeutics was a Boston start-up that designed a cancer pill, STX-478, aimed only at the mutated form of a growth protein called PI3K-alpha, sparing the normal form. Eli Lilly bought the programme in 2025."@en ;
  schema:url <https://onco.cc/companies/scorpion-therapeutics/>, <https://www.scorpiontx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.scorpiontx.com/>, <https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/q125lillysalesandearningsp.htm>, <https://www.sec.gov/Archives/edgar/data/1811858/000095012324006593/primary_doc.xml> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> .